2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
11
Lymphoid
10
Myeloid
3
Sarcoma
1
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
271
Leukemia, Myeloid, Acute
258
Myelodysplastic Syndromes
254
Anemia
245
Leukemia
228
Neoplasms
211
Precursor Cell Lymphoblastic Leukemia-Lymphoma
182
Leukemia, Myelomonocytic, Chronic
151
Multiple Myeloma
138
Venous Thromboembolism
137
Myeloproliferative Disorders
131
Leukemia, Lymphocytic, Chronic, B-Cell
126
Lymphoma
119
Lymphoma, Non-Hodgkin
118
Thrombocytopenia
117
Hodgkin Disease
103
Anemia, Aplastic
97
Febrile Neutropenia
86
Hematologic Neoplasms
82
Anemia, Refractory
82
Primary Myelofibrosis
81
Lymphoma, Follicular
81
Congenital Abnormalities
81
Leukemia, Myeloid, Chronic-Phase
74
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
73
Blast Crisis
72
Leukemia, Myeloid, Accelerated Phase
69
Lymphoma, Mantle-Cell
68
Neoplasms, Plasma Cell
66
Myelodysplastic-Myeloproliferative Diseases
65
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemorrhagic Disorders
×
Classical hematology
×
Clear all
NCT02055781
2021-11-18
PAC326
CTI BioPharma
Phase 3
Terminated
311 enrolled
12 charts